Results
author = "SCHEEN, André"
Les statines dans la prise en charge des dyslipidémies
Author(s) :
SCHEEN, André
Description :
Les statines, en complément des mesures hygiéno-diététiques, occupent une place de premier choix dans la prévention des maladies cardiovasculaires. En inhibant l’enzyme HMG-CoA réductase, ces médicaments diminuent les concentrations de cholestérol total et LDL de façon dose-dépendante. Par ailleurs,...
Repository :
ORBi (University of Liège)
Language(s) :
French
Reduction comparable des nouveaux cas de diabete de type 2 sous sartan et sous inhibiteur de l'enzyme de conversion de l'angiotensine: comparaison des meta-analyses des essais prospectifs randomises. Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials
Author(s) :
Scheen, André
Description :
This paper aims at comparing two meta-analyses of clinical trials having investigated the effect of the inhibition of the renin-angiotensin system either with an angiotensin converting enzyme inhibitor (ACEI) or with a selective angiotensin receptor blocker (ARB) on the incidence of new cases of typ...
Repository :
ORBi (University of Liège)
Language(s) :
French
Vers une tritherapie orale dans le traitement pharmacologique du diabete de type 2? Towards a tripple oral therapy in the pharmacological treatment of type 2 diabetes?
Author(s) :
Scheen, André
Description :
Type 2 diabetes is a complex disease combining several disturbances in various organs, especially a defect of insulin secretion by the pancreas, an increased production of glucose by the liver and a reduced insulin-mediated glucose uptake by the skeletal muscle. Each of these abnormalities can be, a...
Repository :
ORBi (University of Liège)
Language(s) :
French
L'etude clinique du mois. Treating to New Targets": plaidoyer pour une valeur cible de cholesterol LDL egale ou inferieure a 75 mg/dl chez tout patient coronarien." Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease"
Author(s) :
Scheen, André
Description :
The "Treating to New Targets" (TNT) trial compared atorvastatin 80 mg (aiming at reducing LDL cholesterol < or = 75 mg/dl) and atorvastatin 10 mg (LDL < or = 100 mg/dl as target) in 10,001 patients with stable coronary heart disease followed up for 5 years. A reduction of major cardiovascular events...
Repository :
ORBi (University of Liège)
Language(s) :
French
Retrait du rofecoxib (Vioxx): a propos de la securite cardiovasculaire des anti-inflammatoires non steroidiens cox-2 selectifs. Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?
Author(s) :
Scheen, André
Description :
Rofecoxib (Vioxx), the first COX-2 selective non-steroidal anti-inflammatory drug (NSAID), was recently withdrawn by Merck Sharp & Dohme. Indeed, both observational studies and randomised clinical trials showed that rofecoxib is associated with a significantly increased risk of acute myocardial infa...
Repository :
ORBi (University of Liège)
Language(s) :
French
Comment j'explore...le risque cardio-vasculaire absolu a 10 ans: de Framingham 1998 a SCORE 2003. How I explore...the absolute cardiovascular risk at 10 years: from Framingham 1998 to SCORE 2003
Author(s) :
Scheen, André
Description :
Prevention of cardiovascular diseases should primarily focus on high-risk individuals. In the absence of atherosclerosis manifestations, such persons may be screened by the calculation of the absolute risk of complications during the next ten years or extrapolated at the age of 60 years. This calcul...
Repository :
ORBi (University of Liège)
Language(s) :
French
Actualites therapeutiques 2003-2004. New advances in drug therapy in 2003-2004
Author(s) :
Scheen, André
Description :
The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The main characteristics of each molecule and its modalities of appropriate use in clinical practice will be emphasized. Both the efficacy an...
Repository :
ORBi (University of Liège)
Language(s) :
French
Le medicament du mois. Ezetimibe (Ezetrol). Ezetimibe (Ezetrol)
Author(s) :
Scheen, André
Description :
Ezetimibe (Ezetrol), recently launched in Belgium by Merck Sharp& Dohme and Schering Plough, is presented as 10 mg tablets. It belongs to a new class of lipid-lowering agents that selectively inhibit the intestinal absorption of cholesterol and phytosterols. Its mechanism of action results in a syne...
Repository :
ORBi (University of Liège)
Language(s) :
French
Le medicament du mois. Insuline glargine (Lantus). Medication of the month. Insulin glargine (Lantus)
Author(s) :
Scheen, André
Description :
Insulin glargine (Lantus) is a human insulin analogue produced by recombinant DNA technology and recently launched by Aventis. Modification of the human insulin molecule at position A21 and at the C-terminus of the B-chain results in the formation of a stable compound that is soluble at pH 4.0, but ...
Repository :
ORBi (University of Liège)
Language(s) :
French
Le medicament du mois. Rosuvastatine (Crestor). Drug of the month. Rosuvastatin (Crestor)
Author(s) :
Scheen, André
Description :
Rosuvastatin (Crestor) has been recently launched in Belgium by AstraZeneca. This new statin is indicated for the treatment of primary hypercholesterolaemia or combined dyslipidaemia, when changes in dietary habits are insufficient. Direct comparative randomised clinical trials with other statins de...
Repository :
ORBi (University of Liège)
Language(s) :
French